Preview

Системные гипертензии

Расширенный поиск

Применение ингибиторов ангиотензинпревращающего фермента в лечении артериальной гипертонии

Аннотация

На первом месте по числу назначений антигипертензивных средств находятся ингибиторы ангиотензинпревращающего фермента (ИАПФ) - 70,7%. Согласно химической классификации ИАПФ делятся на 3 группы в зависимости от наличия в молекуле ИАПФ окончания для присоединения к цинксодержащему рецептору мембраны клетки: 1-я группа содержит сульфгидрильную группу, 2-я группа - карбоксильную группу, 3-я группа - фосфорильную (фосфинильную) группу. У ИАПФ имеются многочисленные положительные эффекты, дающие им право занимать лидирующие позиции среди назначаемых антигипертензивных средств. ИАПФ являются препаратами первого выбора при наличии у больных АГ сопутствующей ХСН, а также после перенесенного инфаркта миокарда. ИАПФ показаны пациентам с АГ с сопутствующей ИБС, так как оказывают положительные эффекты на атеросклеротический процесс и состояние фибринолитической системы.

Об авторе

А. С. Галявич
Казанский государственный медицинский университет
Россия


Список литературы

1. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиол. журн. 2006; 4: 45-50.

2. Ferreira S.H. A bradikinin - potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol Chemother 1965; 24: 163-9.

3. Yang H.Y, Erdos E.G, Levin E. A dipeptidyl carboxypeptidase that converts angiotensin-1 and inactivates bradykinin. Biochim Biophis Acta 1970; 214: 374-6.

4. Cushman D.W, Ondetti M.A. Personal and historical perspectives: History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hyperetension 1991; 17: 589-92.

5. Patchett A.A, Harris E, Tristram E.W et al. A new class of angiotensin - converting enzyme inhibitors. Nature 1980; 288: 280-3.

6. Opie L.H. Angiotensin converting enzyme inhibitors. Authors Publishing House, New York, 1992.

7. Johnston C.I. Angiotensin - converting enzyme inhibitors. In: Robertson J.I, Nicholson M.G. (ed.) The renin - angiotensin system. London, New York: Gower Medical Publishing 1993; 87.1-87.15.

8. Murdoch D, Tavish D. Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. Drugs 1992; 43: 123-40.

9. Wagstaff A.J, Davis R, Mc Tavish D. Fosinopril: a reapprasal of its pharmacological efficacy in essential hypertension. Drugs 1996; 51: 777-91.

10. Lund-Johansen P, Omvik P. Long - term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension. J Hypertens 1984; 2: S49-50.

11. Ibsen H, Egan B, Osterzeil K, Vander A, Julius S. Reflex - hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans. Hypertension 1983; 5 (suppl. I): I-184-I-9.

12. Dunn G.F, Oigman W, Ventura H.O et al. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984; 53: 105-8.

13. Simon A.C, Levenson J.A, Bouthier J et al. Effects of acute and chronic angiotensin enzyme inhibition on large arteries in human hypertension. J Cardiovasc Pharmacol 1985; 7: S45-51.

14. Cody R.J, Tarazi R.C, Bravo E.L, Fouad F.M. Haemodynamics of orallyactive converting enzyme inhibitor (SQ 14225) in hypertensive patients. Clin Sci Mol Med 1978; 55: 453-9.

15. Fouad F.M, Tarazi R.C, Bravo E.L. Cardiac and haemodynamic effects of enalapril. J Hypertens 1983; 1 (suppl. 1): 135-42.

16. Fagard R, Amery A, Reybrouck T et al. Acute and chronic systemic and hemodynamic effects of angiotensin converting enzyme inhibition with captopril in hypertensive patients. Am J Cardiol 1980; 46: 295-300.

17. Tarazi R.C, Bravo E.L, Fouad F.M et al. Hemodynamic and volume changes associated with captopril. Hypertension 1980; 2: 576-85.

18. Muiesan G, Alicandri C.L, Agabiti-Rosei E et al. Angiotensin - converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension. Am J Cardiol 1982; 49: 1420-4.

19. Horning B, Landmesser U, Kohler C et al. Comparative effects of ace inhibition and angiotensin II type receptor antagonism on bioavailability of nitric oxide in patients with coronary heart disease: role of superoxide dismutase. Circulation 2001; 103: 799-805.

20. Horning B, Arakawa N, Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J 1998; 19 (Suppl. G): G48-53.

21. Brunner H.R, Gavras H, Waeber B et al. Oral angiotensin - converting enzyme inhibitor in long - term treatment of hypertensive patients. Ann Intern Med 1979; 90: 19-23.

22. Gavras H, Brunner H.R, Turini G.A et al. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298: 991-5.

23. Vander A.J, Geelhoed G.W. Inhibition of renin secretion by angiotensin II. Proc Soc Exp Biol Med 1965; 120: 399-403.

24. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta - analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.

25. Brilla C.G, Janicki J.S, Weber K.T. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83: 1771-9.

26. Weber J.R. Left ventricular hypertrophy: its prevalence, etiology and significance. Clin Cardiol 1991; 14 (Suppl. III): 13-7.

27. Peng H, Carretero O, Vuljaj N et al. Angiotensin-Converting Enzyme Inhibitors: A New Mechanism of Action. Circulation 2005; 112 (16): 2436-45.

28. Schlueter W.A, Battle D.C. Renal effects of antihypertensve drugs. Drugs 1989; 37: 900-25.

29. Hall J.E. Intrarenal actions of converting enzyme inhibitors. Am J Hypertns 1989; 2: 875-84.

30. Nishijama K, Igari T, Nanda S, Ishii M. Long - term effects of delapril on renal function annd urinary excretion of kallikrein, prostaglandin E2, and thromboxan B2 in hypertensive patients. Am J Hypertens 1991; 4: 52S-3S.

31. Brichard S, Lambert A.E. Perindopril safety and tolerance in at risk patients. Drugs 1990; 39 (Suppl. 1): 64-70.

32. Vaughan D.E, Lazos S.A, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995; 95: 995-1001.

33. Ridker P.M, Gaboury C.L, Conlin P.R et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation 1993; 87: 1969-73.

34. Emeis J.J, Tranquille N. On the role of bradykinin in secretion from vascular endothelial cells. Agents Actions 1992; 38: 285-91.

35. Brown N.J, Nadeau J, Vaughan D.E. Selective stimulation of tissue - type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77: 522-5.

36. Pitt B. Potential role of angiotensin converting enzyme inhibitors in the treatment of atherosclerosis. Eur Heart J 1995; 16: 49-54.

37. Schoelkens B.A, Landgraf W. ACE inhibition and atherosclerosis. Can J Physiol Pharm 2002; 80: 354-9.

38. Dagenais G.R, Pogue J, Fox K et al. Angiotensin - converting - enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368 (9535): 581-8.

39. Zanchetti A, Crepaldi G, Bond G et al. Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progreesion of Asymptomatic Carotid Atherosclerosis. Stroke 2004; 35:

40. Zhuo J, Moeller I, Jenkins T et al. Mapping tissue angiotensin - converting enzyme and angiotensin AT1, AT2 and AT4 receptors. J Hypertens 1998; 16: 2027-37.

41. Opie L.H. Angiotensin Converting Enzyme Inhibitors. The Advance Continues. Third Edition. Authors Publishing House. New York. 1999.

42. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin - converting - enzyme inhibitor, ramipril, on cardiovascular events in high - risk patients. N Engl J Med 2000; 342: 145-53.

43. Bosch J, Yusuf S, Pogue J et al. HOPE Investigators. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 699-702.

44. PROGRESS Collaborative Group. Randomised trial of a perindopril - based blood - pressure - lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.

45. Hansson L, Lindholm L, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial on Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.

46. Hansson L, Lindholm L, Niskanen L et al. Effect of angiotensin - converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611-6.

47. Wing L.M, Reid C.M, Ryan P et al. A comparison of outcomes with angiotensin - converting enzyme inhibitors and diuretics for hypertension in the erderly. N Engl J Med 2003; 348: 583-92.

48. Рекомендации ВНОК "Профилактика, диагностика и лечение артериальной гипертензии", 2-й пересмотр. М., 2004.

49. Kang P.M, Landau A.J, Eberhardt R.T, Frishman W.H. Angiotensin II receptor antagonists: a new approach to blockade of the renin - angiotensin system Am Heart J 1994; 127: 1388-401.

50. Ferner R.E, Simpson J.M, Rawlins M.D. Effects of intradermal bradykininn after inhibition of angiotensin converting enzyme. Br Med J 1987; 294: 1119-20.


Рецензия

Для цитирования:


Галявич А.С. Применение ингибиторов ангиотензинпревращающего фермента в лечении артериальной гипертонии. Системные гипертензии. 2006;(2):46-49.

Просмотров: 0


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2075-082X (Print)
ISSN 2542-2189 (Online)